Celyad Oncology S.A. (CYAD)

Celyad Oncology S.A. (CYAD) Healthcare & Pipeline Overview

Celyad Oncology S.A. is a Belgian clinical-stage biotechnology firm focused on developing innovative chimeric antigen receptor T (CAR-T) cell therapies for oncology. The company's pipeline features allogeneic and autologous CAR-T candidates, including CYAD-101, CYAD-211, and CYAD-02, targeting significant unmet medical needs in various cancer indications.

What Is the Investment Thesis for CYAD?

Celyad Oncology S.A. is a clinical-stage biotechnology company focused on developing next-generation CAR-T cell therapies for cancer, presenting a thesis centered on its diversified pipeline and allogeneic platform potential. The company's lead candidates, CYAD-101 (metastatic colorectal cancer), CYAD-211 (multiple myeloma), and CYAD-02 (AML/MDS), are all in Phase 1 or Phase 1b clinical trials, representing significant market opportunities upon successful development. The allogeneic CAR-T approach, particularly with CYAD-101 and CYAD-211, offers potential advantages in scalability, manufacturing efficiency, and broader patient accessibility compared to autologous therapies. Strategic licensing agreements, such as with Novartis for allogeneic CAR-T patents and Horizon Discovery for shRNA technology, underpin its intellectual property and technological foundation. Key value drivers include positive clinical trial data readouts, which could de-risk its pipeline and attract further partnerships or funding. The company's focus on both hematologic malignancies and solid tumors, including the preclinical CYAD-203, provides a broad therapeutic scope. However, the inherent risks of clinical development, including trial outcomes, regulatory hurdles, and intense competition within the CAR-T space, remain critical considerations for investors.

Based on FMP financials and quantitative analysis

CYAD Key Highlights

• Market capitalization of $14.24M reflects its early-stage development and small-cap biotechnology status.
• A P/E ratio of 13.4 indicates profitability, which is uncommon for a clinical-stage biotech and warrants further investigation into its revenue sources, likely from licensing agreements.
• Impressive Profit Margin of 3833.3% and Gross Margin of 9195.2% suggest significant revenue generation relative to costs, potentially driven by non-operational income or specific licensing milestones.
• A Beta of 1.69 indicates higher volatility compared to the broader market, typical for a biotechnology company with a pipeline-driven valuation.
• The company does not pay a dividend, consistent with clinical-stage biopharmaceutical companies that reinvest earnings into research and development.

Who Are CYAD's Competitors?

CYAD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CYAD's Key Strengths?

• Diversified pipeline with both allogeneic and autologous CAR-T candidates addressing multiple cancer indications.
• Strategic licensing agreements with major players like Novartis, validating its technology and intellectual property.
• Focus on allogeneic CAR-T therapies offers potential advantages in scalability and accessibility over autologous approaches.
• Proprietary shRNA technology for enhanced CAR-T cell engineering.

What Are CYAD's Weaknesses?

• All lead product candidates are in early-stage clinical trials (Phase 1/1b), indicating a long and uncertain path to market.
• Relatively small company with 35 employees, potentially limiting resources compared to larger pharmaceutical competitors.
• High cash burn typical of clinical-stage biotechnology companies, requiring continuous funding.
• Significant reliance on successful clinical trial outcomes and regulatory approvals for future viability.

What Could Drive CYAD Stock Higher?

• Release of further clinical data from the Phase 1b trial of CYAD-101 for metastatic colorectal cancer, expected to provide insights into safety and preliminary efficacy.
• Updates on the progression of CYAD-211's Phase 1 clinical trial for relapsed / refractory multiple myeloma, including patient enrollment and initial safety observations.
• Continued development and preclinical data generation for CYAD-203, a non-gene edited allogeneic CAR-T candidate for solid tumors, which could lead to an Investigational New Drug (IND) application.
• Potential for new strategic collaborations or licensing agreements building on existing partnerships with companies like Novartis and Horizon Discovery Group.

What Are the Key Risks for CYAD?

• Financial-distress signal — its Altman Z-Score of -41.94 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failure for lead candidates (CYAD-101, CYAD-211, CYAD-02) due to lack of efficacy, unacceptable safety profiles, or unforeseen adverse events, which could significantly devalue the company.
• Intense competition within the CAR-T cell therapy space from larger, well-funded pharmaceutical companies and other biotechnology firms developing similar or superior technologies.
• Regulatory hurdles and delays in obtaining necessary approvals from health authorities for its CAR-T therapies, extending development timelines and increasing costs.
• Significant capital requirements for ongoing research and development, potentially leading to future equity dilution if additional financing is needed.
• Intellectual property challenges or disputes regarding its CAR-T technologies, which could impact its competitive position and ability to commercialize products.

What Are the Growth Opportunities for CYAD?

• Growth opportunity 1: Advancement of CYAD-101 for Metastatic Colorectal Cancer. CYAD-101, an allogeneic CAR-T candidate, is currently in Phase 1b clinical trials for metastatic colorectal cancer (mCRC). Colorectal cancer is a leading cause of cancer-related deaths globally, with mCRC presenting a particularly challenging prognosis. The global market for colorectal cancer therapeutics is substantial, estimated to be in the tens of billions of dollars annually. Successful progression of CYAD-101 through clinical development, especially demonstrating efficacy and safety in later-stage trials, could position Celyad Oncology to address a significant patient population with limited effective treatment options, offering a competitive advantage through its off-the-shelf allogeneic approach.
• Growth opportunity 2: Development of CYAD-211 for Relapsed/Refractory Multiple Myeloma. CYAD-211, an shRNA-based allogeneic CAR-T candidate, is in Phase 1 clinical trials for relapsed/refractory multiple myeloma (RRMM). Multiple myeloma is the second most common hematologic malignancy, and RRMM patients have a poor prognosis, creating a high demand for innovative therapies. The global multiple myeloma market is projected to reach over $30 billion by the early 2030s. The allogeneic nature of CYAD-211, combined with its shRNA technology to prevent graft-versus-host disease, could offer a significant advantage over existing autologous CAR-T therapies by providing a more accessible and potentially safer treatment option for a broad patient base.
• Growth opportunity 3: Progress of CYAD-02 for Acute Myeloid Leukemia and Myelodysplastic Syndromes. CYAD-02, an autologous CAR-T candidate, is in Phase 1 clinical trials for relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). AML and MDS are aggressive hematologic malignancies with high unmet medical needs, particularly in the relapsed/refractory setting. The global AML market alone is expected to exceed $5 billion by the late 2020s. Demonstrating positive clinical outcomes for CYAD-02 would validate Celyad's autologous CAR-T platform and provide a crucial therapeutic option for patients who have exhausted standard treatments, establishing a foothold in these challenging disease areas.
• Growth opportunity 4: Preclinical Development of CYAD-203 for Solid Tumors. The preclinical candidate CYAD-203, a non-gene edited allogeneic CAR-T designed to co-express IL-18 with NKG2D ligands, targets solid tumors. Solid tumors represent the vast majority of cancer cases and are notoriously difficult to treat with current CAR-T therapies due to challenges like tumor microenvironment suppression and antigen heterogeneity. The global solid tumor market is immense, valued in the hundreds of billions of dollars. Successful preclinical and subsequent clinical development of CYAD-203 could unlock a massive market opportunity for Celyad, potentially overcoming current limitations of CAR-T in solid tumors through its novel cytokine and ligand co-expression strategy.
• Growth opportunity 5: Leveraging Allogeneic CAR-T Platform and Strategic Partnerships. Celyad Oncology's allogeneic CAR-T platform, utilized in candidates like CYAD-101 and CYAD-211, represents a significant growth driver. This 'off-the-shelf' approach offers advantages in manufacturing scalability, cost-effectiveness, and faster patient access compared to individualized autologous therapies. Furthermore, strategic licensing agreements, such as with Novartis for allogeneic CAR-T patents and Horizon Discovery for shRNA technology, provide a strong intellectual property foundation and access to advanced genetic engineering tools. These partnerships not only validate Celyad's technology but also provide potential avenues for future collaboration, co-development, and commercialization, expanding its market reach and accelerating pipeline progression.

What Opportunities Does CYAD Have?

• Successful progression of lead candidates (CYAD-101, CYAD-211, CYAD-02) through later-stage clinical trials.
• Expansion of its allogeneic CAR-T platform into new indications or through new partnerships.
• Potential for breakthrough therapies in solid tumors with preclinical candidate CYAD-203.
• Increased demand for advanced cell therapies in oncology, driven by unmet medical needs and technological advancements.

What Threats Does CYAD Face?

• High failure rates inherent in clinical drug development, particularly in early phases.
• Intense competition from other biotechnology and pharmaceutical companies developing CAR-T and other cell therapies.
• Stringent regulatory hurdles and lengthy approval processes for novel cell therapies.
• Potential for adverse clinical trial results or safety concerns that could halt development or reduce market potential.

What Are CYAD's Competitive Advantages?

• Proprietary allogeneic CAR-T platform, which aims to overcome manufacturing and logistical challenges of autologous therapies, potentially offering an 'off-the-shelf' solution.
• Strategic licensing agreements, including a significant agreement with Novartis for U.S. patents related to allogeneic CAR-T cells, bolstering its intellectual property portfolio.
• Utilization of short hairpin RNA (shRNA) technology, licensed from Horizon Discovery Group, to engineer CAR-T cells for enhanced safety and efficacy.
• A diversified clinical pipeline targeting both hematologic malignancies and solid tumors, including novel approaches like IL-18 co-expression for solid tumors.
• Early-stage clinical data and preclinical validation for its novel CAR-T constructs, demonstrating proof-of-concept for its therapeutic strategies.

What Does CYAD Do?

Celyad Oncology SA, founded in 2004 and headquartered in Mont-Saint-Guibert, Belgium, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company's strategic focus is on leveraging both allogeneic and autologous CAR-T approaches to address a broad spectrum of oncological indications. Its lead product candidates represent distinct therapeutic avenues within the CAR-T landscape. CYAD-101, an allogeneic CAR-T candidate, is currently in a Phase 1b clinical trial for the treatment of metastatic colorectal cancer, a significant area of unmet medical need. Another key candidate, CYAD-211, is a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is progressing through Phase 1 clinical trials for relapsed / refractory multiple myeloma. Complementing its allogeneic efforts, Celyad Oncology also develops autologous therapies, exemplified by CYAD-02, an autologous CAR-T candidate in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Beyond its clinical pipeline, the company maintains a robust preclinical program, including CYAD-203, a non-gene edited allogeneic CAR-T candidate designed to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for solid tumors. Celyad Oncology has strategically built its intellectual property and technological capabilities through key partnerships, including a licensing agreement with Novartis International AG concerning United States patents related to allogeneic CAR-T cells, and research and development collaboration and license agreements with Horizon Discovery Group plc for the utilization of its shRNA technology. The company, formerly known as Celyad SA, rebranded to Celyad Oncology SA in June 2020, signaling its sharpened focus on oncology therapeutics. With 35 employees, Celyad Oncology operates at the forefront of cellular immunotherapy research, aiming to bring innovative cancer treatments to patients worldwide.

What Products and Services Does CYAD Offer?

• Discover and develop chimeric antigen receptor T (CAR-T) cell therapies for various types of cancer.
• Advance allogeneic CAR-T candidates, such as CYAD-101 for metastatic colorectal cancer and CYAD-211 for multiple myeloma.
• Develop autologous CAR-T candidates, including CYAD-02 for acute myeloid leukemia and myelodysplastic syndromes.
• Conduct preclinical research on next-generation allogeneic CAR-T therapies like CYAD-203 for solid tumors.
• Utilize proprietary short hairpin RNA (shRNA) technology to enhance CAR-T cell performance and safety.
• Engage in strategic licensing and collaboration agreements with major pharmaceutical and biotechnology companies, such as Novartis and Horizon Discovery Group.

How Does CYAD Make Money?

• Primarily generates revenue through strategic licensing agreements for its proprietary CAR-T cell technologies and intellectual property, such as the agreement with Novartis.
• Aims to generate future revenue from the commercialization of its CAR-T cell therapy products upon successful clinical development and regulatory approval.
• Secures funding through equity financing and potentially non-dilutive grants to support ongoing research and development activities for its extensive pipeline.
• Engages in research and development collaborations, which may include milestone payments and royalties from partners utilizing its technologies.

What Industry Does CYAD Operate In?

Celyad Oncology S.A. operates within the highly innovative and competitive Biotechnology industry, specifically focusing on cell and gene therapies for oncology. The CAR-T cell therapy market is characterized by rapid technological advancements and significant unmet medical needs, particularly in refractory cancers. This market is projected for substantial growth, driven by increasing cancer incidence and the promise of personalized medicine. Celyad Oncology's positioning with both allogeneic and autologous CAR-T candidates allows it to address different segments of this market. Allogeneic therapies, like CYAD-101 and CYAD-211, are particularly relevant as they aim to overcome the logistical and cost challenges associated with personalized autologous treatments, potentially expanding patient access. The competitive landscape includes established pharmaceutical giants and numerous biotech startups, all vying for breakthroughs in CAR-T technology. Celyad's strategy of leveraging proprietary shRNA technology and strategic licensing agreements, such as with Novartis, is crucial for maintaining a competitive edge and advancing its pipeline in this dynamic environment.

Who Are CYAD's Key Customers?

• Future patients suffering from various cancers, including metastatic colorectal cancer, multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
• Oncology healthcare providers and hospitals seeking advanced cellular immunotherapies for their patients.
• Pharmaceutical and biotechnology companies interested in licensing Celyad's CAR-T technology or collaborating on drug development.
• Research institutions and academic centers involved in oncology and cell therapy research.

Celyad Oncology S.A. (CYAD) Valuation Context

Valued at $14.24M, CYAD is classified as a micro-cap stock. Relative to its peer group, CYAD's quantitative score of 57/100 is below the peer average of 76/100.

CYAD Revenue & Earnings Trend

In Q4 2024, CYAD generated $172K in top-line revenue, marking a sequential increase of 1128.6%. The company recorded a net loss of $2.8M, with diluted EPS of $-0.07.

Company Profile

Celyad Oncology S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Mont-Saint-Guibert, BE. The company is led by CEO Georges Rawadi. CYAD has traded publicly since 2015.

P/E 13.4Key Financial Metrics

Return on assets is 18.7%, showing how much profit it generates from its asset base. CYAD trades at a trailing price-to-earnings ratio of 13.38, below the Healthcare sector average of ~23x. Its free cash flow yield is -64.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Celyad Oncology S.A.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -41.94 places it in the distress zone, a signal of elevated financial risk.

CYAD Financials

CYAD Latest News

No recent news available for CYAD.

CYAD Analyst Consensus

CYAD MoonshotScore

Celyad Oncology S.A. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources